SCHEMBL4085359

SCHEMBL4085359

N#Cc1ccc(F)c(C(O)c2ccccc2F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EEF2K O00418 1/20 0.40
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
HIF1A Q16665 1/20 0.35
TOP2A P11388 1/20 0.35
TOP2B Q02880 1/20 0.35
CHEK1 O14757 1/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
ABL1 P00519 1/20 0.35
NTRK1 P04629 1/20 0.35
LCK P06239 1/20 0.35
FYN P06241 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
IGF1R P08069 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30251256 0.81 TOP2A (0.48) EEF2KCES2CES1HIF1ATOP2A
SCHEMBL23882902 0.81 TOP2A (0.48) EEF2KCES2CES1HIF1ATOP2A
SCHEMBL4085392 0.79 CYP3A4 (0.42) TOP2ATOP2BCA1CA2
SCHEMBL4901994 0.79 ALOX5 (0.39) CDK8TSHRALDH1A1TNF
SCHEMBL4085361 0.79 TOP2A (0.40) CES2CES1TOP2ATOP2BMGLL
SCHEMBL2861781 0.78 CES2 (0.38) CES2CES1TOP2ATOP2BACLY
SCHEMBL30057873 0.78 CES2 (0.52) CES2CES1ALDH1A1GAA
SCHEMBL1902230 0.78 CES2 (0.52) CES2CES1ALDH1A1GAA
SCHEMBL7216331 0.77 GAA (0.41) MGLLCA2SMN1; SMN2ALDH1A1GAA
SCHEMBL30876218 0.76 GRIN2B (0.39) ACLYCA2SMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 EEF2K 1643/4885CES2 4697/4885CES1 3478/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 EEF2K 1509/4885CES2 4671/4885CES1 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.